Reuters logo
7 months ago
BRIEF-Can Fite BioPharma phase II trial to treat NAFLD/NASH expected to commence in 2017
December 16, 2016 / 12:14 PM / 7 months ago

BRIEF-Can Fite BioPharma phase II trial to treat NAFLD/NASH expected to commence in 2017

1 Min Read

Dec 16 (Reuters) - Can Fite Biopharma Ltd

* New preclinical data show Can-Fite's namodenoson (cf102) inhibits liver fibrosis

* Can Fite BioPharma -new data suggests anti-fibrotic effect of drug and supports its development as agent to combat non-alcoholic fatty liver disease

* Phase II trial to treat NAFLD/NASH expected to commence in 2017

* Can Fite BioPharma Ltd- advancing Aamodenoson into a phase ii trial expect to commence in coming months through medical institutions in Israel Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below